DrugPatentWatch Database Preview

Aztreonam - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for aztreonam and what is the scope of patent protection?

Aztreonam is the generic ingredient in four branded drugs marketed by Gilead, Bristol Myers Squibb, Fresenius Kabi Usa, and West-ward Pharms Int, and is included in five NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aztreonam has fifty-five patent family members in twenty-one countries.

There are eight drug master file entries for aztreonam. Three suppliers are listed for this compound.

Summary for aztreonam

International Patents:	55
US Patents:	4
Tradenames:	4
Applicants:	4
NDAs:	5
Drug Master File Entries:	8
Suppliers / Packagers:	3
Bulk Api Vendors:	74
Clinical Trials:	51
Patent Applications:	7,570
Formulation / Manufacturing:	see details
Drug Prices:	Drug price trends for aztreonam
DailyMed Link:	aztreonam at DailyMed

See drug prices for aztreonam

Recent Clinical Trials for aztreonam

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
University of Washington	Phase 2/Phase 3
Hospital Universitari Joan XXIII de Tarragona.	Phase 2/Phase 3

See all aztreonam clinical trials

Pharmacology for aztreonam

Drug Class

Monobactam Antibacterial

Medical Subject Heading (MeSH) Categories for aztreonam

Anti-Bacterial Agents

Synonyms for aztreonam

(2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate

(2S,3S)-3-({(2Z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam)

(3S)-2-Oxo-3beta-[2-(2-aminothiazole-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetylamino]-4alpha-methylazetidine-1-sulfonic acid

(E)-2-((((2-Amino-4-thiazolyl)(((2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl(methylene)amino(oxy)-2-methylpropionic acid

(Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3- azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid

(Z)-aztreonam

[2S-[2|A,3|A(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid

[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid

110A380

2-((((E)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid

2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid

2-(((Z)-(1-(2-Aminothiazol-4-yl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid

2-({[(1E)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid

2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid

2-[(E)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid

2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid

2-[(Z)-[1-(2-aminothiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic acid

2-[[(2-amino-1,3-thiazol-4-yl)-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]carbamoyl]methylidene]amino]oxy-2-methylpropanoic acid

2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic Acid

2-[1-(2-Amino-thiazol-4-yl)-1-((2S,3S)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(Z)-ylideneaminooxy]-2-methyl-propionic acid

5Q55M3D9UA

78110-38-0

99341-02-3

A-9950

AB01563305_01

AB2000129

ABP000466

AC-4330

AC1NUR9Y

AC1NX3U2

AJ-74989

AKOS015840157

AKOS015961777

AKOS015969724

AKOS034796899

AN-12074

API0001576

AS-13760

Azactam

Azetreonam

Azthreonam

Aztreonam (Azactam, Cayston)

Aztreonam, analytical standard

Aztreonam, Antibiotic for Culture Media Use Only

Aztreonam, Pharmaceutical Secondary Standard; Certified Reference Material

Aztreonam, United States Pharmacopeia (USP) Reference Standard

Aztreonam(Azactam, Cayston)/

BC208259

BCP9000372

BCPP000356

BDBM50240480

BIDD:GT0765

BPBio1_000121

BRD-K36547807-001-02-4

BRD-K62607865-001-03-0

BSPBio_000109

BSPBio_002512

CA0151

CAS-78110-38-0

CC-24234

CCG-213342

CCG-220185

CHEBI:161680

CHEBI:94511

CHEMBL158

CHEMBL410081

Corus 1020

CS-1902

DTXSID20244045

E-Aztreonam

G2B4VE5GH8

HMS1568F11

HMS2090K09

HMS2095F11

HMS3712F11

HY-B0129

J10266

KB-47492

MFCD00072145

MLS003915628

MLS006011974

MolPort-002-676-388

MolPort-003-886-345

Monobactam;SQ 26776;Squibb 26776;Azactam;Cayston

NCGC00016936-01

NCGC00016936-02

NCGC00179656-01

NSC-646279

NSC-758913

NSC646279

NSC758913

Pharmakon1600-01505122

Prestwick_914

Prestwick2_000185

Prestwick3_000185

Primbactam

Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(E)))-

Propanoic acid, 2-(((E)-(1-(2-amino-4-thiazolyl)-2-(((2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-

Propanoic acid, 2-[[(Z)-[1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-

PubChem13620

RP18114

S1505

SBI-0206775.P001

SCHEMBL13616074

SCHEMBL37512

SMR002204030

SMR004703537

SO-26776

SPECTRUM1505122

SQ 26776

SQ 28429

SQ-26776

SQ-28429

Squibb 26776

SR-01000841814

SR-01000841814-2

SR-01000841814-3

STL011049

UNII-5Q55M3D9UA

UNII-G2B4VE5GH8

WZPBZJONDBGPKJ-VEHQQRBSSA-N

ZINC12503091

ZINC3830264

US Patents and Regulatory Information for aztreonam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
West-ward Pharms Int	AZTREONAM	aztreonam	INJECTABLE;INJECTION	065286-002	Mar 23, 2011		DISCN	No	No
Fresenius Kabi Usa	AZTREONAM	aztreonam	INJECTABLE;INJECTION	065439-003	Jun 18, 2010	AP	RX	No	No
Bristol Myers Squibb	AZACTAM	aztreonam	INJECTABLE;INJECTION	050580-001	Dec 31, 1986		DISCN	No	No
Bristol Myers Squibb	AZACTAM IN PLASTIC CONTAINER	aztreonam	INJECTABLE;INJECTION	050632-001	May 24, 1989		DISCN	Yes	No
Gilead	CAYSTON	aztreonam	FOR SOLUTION;INHALATION	050814-001	Feb 22, 2010		RX	Yes	Yes			Y
Gilead	CAYSTON	aztreonam	FOR SOLUTION;INHALATION	050814-001	Feb 22, 2010		RX	Yes	Yes			Y

International Patents for aztreonam

Country	Patent Number	Estimated Expiration
Brazil	0116757
European Patent Office	2158901
Israel	156596
Portugal	1353647
Australia	2014271333
Portugal	2158901

Supplementary Protection Certificates for aztreonam

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2158901	122018000044	Germany		PRODUCT NAME: AZTREONAMIYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1353647	2011C/029	Belgium		PRODUCT NAME: AZTREONAM LYSINE; AUTHORISATION NUMBER AND DATE: EU/1/09/543/001 20090923
1353647	C01353647/01	Switzerland		PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: SWISSMEDIC 59389 06.12.2010
1353647	300492	Netherlands		PRODUCT NAME: AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
1353647	C300492	Netherlands		PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1353647	365	Finland